William Blair reaffirmed their outperform rating on shares of MaxCyte (NASDAQ:MXCT – Free Report) in a report published on Tuesday morning, RTT News reports. Separately, Craig Hallum started coverage on MaxCyte in a research note on Wednesday, November 29th. They issued a buy rating and a $7.00 target price on the stock. View Our Latest […]
MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) Director John Joseph Johnston sold 5,000 shares of MaxCyte stock in a transaction on Friday, January 26th. The shares were sold at an average price of $5.12, for a total transaction of $25,600.00. Following the completion of the sale, the director now owns 120,583 shares in the company, […]
MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $4.59, but opened at $4.98. MaxCyte shares last traded at $5.14, with a volume of 235,852 shares changing hands. Wall Street Analyst Weigh In Several research firms have recently issued reports on MXCT. Stephens […]
MaxCyte, Inc. (NASDAQ:MXCT – Free Report) – William Blair lifted their FY2023 EPS estimates for MaxCyte in a research note issued to investors on Tuesday, December 12th. William Blair analyst M. Larew now forecasts that the company will post earnings per share of ($0.41) for the year, up from their prior forecast of ($0.45). William […]
Royce & Associates LP grew its stake in MaxCyte, Inc. (NASDAQ:MXCT – Free Report) by 14.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 307,925 shares of the company’s stock after purchasing an additional 37,800 shares during the period. Royce & Associates […]